MTBVAC

MTBVAC is a candidate vaccine against tuberculosis in humans currently in clinical trials. It is based on a genetically modified form of the Mycobacterium tuberculosis pathogen isolated from humans.[1] Unlike the BCG vaccine, MTBVAC contains all the antigens present in the strains that infect humans.

  1. ^ Martin C (2020). "Update on TB Vaccine Pipeline". Applied Sciences. 10 (7): 2632. doi:10.3390/app10072632.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.